← Leaderboards
Jeffrey Zwicker
Beth Israel Deaconess Medical Center
$3,964,427
Attributed
$8,179,849
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,179,849 · 7
By mechanism
U01$4,347,623 · 1
R34$1,471,753 · 2
R01$1,449,023 · 2
K23$747,390 · 1
R21$164,060 · 1
Top collaborators
- Robert C Flaumenhaft6 shared
- Elliot Chaikof5 shared
- Alok A Khorana3 shared
- Joseph E Italiano1 shared
- Elizabeth Jewell1 shared
- Daniel Robert Kennedy1 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Bruce Furie$39,376,853
- Robert C Flaumenhaft$19,499,862
- Elliot Chaikof$40,570,541
- Barbara C Furie$9,637,605
- Moua Yang$826,968
Others in their field
Top investigators on “Thrombosis”
- Paul M. Ridker · Brigham And Women'S Hospital$59,264,235
- John H Griffin · Scripps Research Institute$29,245,116
- David J. Pinsky · University Of Michigan At Ann Arbor$29,054,903
- Bruce Furie · Beth Israel Deaconess Medical Center$28,093,838
- Denisa D Wagner · Boston Children'S Hospital$24,247,974
- Satya P. Kunapuli · Temple University$22,403,131
Research focus
ThrombosisEventVenousMalignant NeoplasmsCancer PatientThromboplastinPlasmaThrombusMolecularMalignant Neoplasm Of PancreasIn VivoBiological MarkersSamplingTechnologyPancreasColonPreventGenerationsRecording Of Previous EventsMalignant - DescriptorMediatingEvaluationDiagnosisClinical Trials
Grant awards (19)
Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping$631,382
R01 · FY2025 · AT · contact PI
Biomarkers and mechanisms in cancer associated thrombosis$829,929
U01 · FY2022 · HL
Biomarkers and mechanisms in cancer associated thrombosis$874,736
U01 · FY2021 · HL · contact PI
Biomarkers and mechanisms in cancer associated thrombosis$874,736
U01 · FY2020 · HL · contact PI
Vascular Thiol Isomerases in Thrombosis$817,641
R01 · FY2020 · HL · contact PI
Biomarkers and mechanisms in cancer associated thrombosis$874,736
U01 · FY2019 · HL · contact PI
Thromboprophylaxis with rosuvastatin following surgery for ovarian cancer$275,674
R34 · FY2019 · HL · contact PI
Response to PQ12 - Using thiol isomerase inhibitors to diminish cancer induced thrombosis$164,060
R21 · FY2019 · CA
Biomarkers and mechanisms in cancer associated thrombosis$893,486
U01 · FY2018 · HL · contact PI
Risk-adapted thromboprophylaxis of hospitalized cancer patients$235,401
R34 · FY2018 · HL · contact PI
Thromboprophylaxis with rosuvastatin following surgery for ovarian cancer$220,500
R34 · FY2018 · HL · contact PI
Risk-adapted thromboprophylaxis of hospitalized cancer patients$321,168
R34 · FY2017 · HL · contact PI
Thromboprophylaxis with rosuvastatin following surgery for ovarian cancer$165,109
R34 · FY2017 · HL · contact PI
Risk-adapted thromboprophylaxis of hospitalized cancer patients$253,901
R34 · FY2016 · HL · contact PI
Bloodborne tissue factor-bearing microparticles in Trousseau's syndrome$154,758
K23 · FY2011 · HL · contact PI
Bloodborne tissue factor-bearing microparticles in Trousseau's syndrome$154,758
K23 · FY2010 · HL · contact PI
Bloodborne tissue factor-bearing microparticles in Trousseau's syndrome$154,758
K23 · FY2009 · HL · contact PI
Bloodborne tissue factor-bearing microparticles in Trousseau's syndrome$154,758
K23 · FY2008 · HL · contact PI
Bloodborne tissue factor-bearing microparticles in Trousseau's syndrome$128,358
K23 · FY2007 · HL · contact PI